Effective radioiodide therapy of metastatic thyroid cancers requires uptake of radioiodide via the sodium/iodide symporter (NIS), and optimally, its incorporation into tyrosine residues of thyroglobulin to increase the residence time of the isotope. The gene discussed is SLC5A5; the disease is thyroid gland carcinoma.